Article
CYP2C19 genetic variants affect nelfinavir pharmacokinetics and virologic response in HIV-1-infected children receiving highly active antiretroviral therapy.
Journal of acquired immune deficiency syndromes (1999) - 1 Jul 2010
Saitoh Akihiko, Capparelli Edmund, Aweeka Francesca, Sarles Elizabeth, Singh Kumud K, Kovacs Andrea, Burchett Sandra K, Wiznia Andrew, Nachman Sharon, Fenton Terence, Spector Stephen A
Abstract excerpt
BACKGROUND: The objective of this research was to identify the impact of genetic variants of P-glycoprotein (ABCB1) and cytochrome P450 (CYP) on nelfinavir pharmacokinetics and response to highly active antiretroviral therapy (HAART) in HIV-1-infected children. METHODS: HIV-1-infected children (n = 152) from Pediatric AIDS Clinical Trial Group 366 or 377 receiving nelfinavir as a component of HAART were...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
